News

Advances in technology are creating new opportunities for health insurers to move beyond the role of payer to trusted partner in the protection and extension of our health and independence as we age.

A majority of oncology drugs-particularly older cancer drugs-had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street.

FDA tentatively approved the abbreviated new drug application (ANDA) for generic quetiapine fumarate extended-release tablets (brand Seroquel XR, AstraZeneca) to treat schizophrenia and manic/mixed episodes associated with bipolar disorder.

The advantages of using an advanced clinical decision support system fall into four general “reducing” categories. Here they are.

It’s time for stakeholders to cooperate in order to limit the wasted spending on prescription medications and chart a path to collectively improving value derivation.

Consumers want more, and it’s time to deliver. Here’s how health insurers can retain current members and attract new ones.

MCOs are going to have to step up their efforts to impact the growing opioid epidemic in this country.

The US Drug Enforcement Administration (DEA) has reduced the amount of almost every Schedule II opiate and opioid medication that may be manufactured in the US by 25% or more.

As Mylan continues to face criticism over price hikes on its EpiPen epinephrine injection, the company agreed to a $465 million settlement with the U.S. Department of Justice and other agencies for overcharging on the EpiPen.

Executives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs.

Faced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?

In April CMS released final rules outlining significant updates to the Medicaid managed care program. Here are the top issues to watch.

Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments.

What is the future of Healthcare Exchanges? And what is the future of Obamacare in general? Healthcare executives weigh in.

Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.

While healthcare has flown under the radar for much of this election season, it’s a topic that was not ignored at the Academy of Managed Care Pharmacy (AMCP) Nexus in National Harbor, Maryland.

Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.

A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.

Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.

Understanding both candidates proposals can help executives make informed decisions.

Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.

Here are the top 10 states that deliver the best healthcare services, according to personal-finance website WalletHub.

As the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.

In 2014, nearly 2 million Americans met the diagnostic criteria for a past-year prescription opioid use disorder, and at least 14,000 people died from a prescription opioid overdose. Read about the top drivers and risk factors.

Two reports highlight areas of elderly care that healthcare systems and health plans should avoid.

FDA recently expanded the use of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) to treat cystic fibrosis in children aged 6 to 11 years who have two copies of the F508del mutation.

An independent study considers the global adoption of value-based healthcare across 25 countries.

Five key areas of healthcare, the candidates’ proposals for them, and analysis from experts.